Board of Directors
Prof. Mordechai (Mottie) Chevion (CSO).
Mordechai “Mottie” Chevion, professor of biochemistry and incumbent of the Dr. William Ganz Chair of Heart Studies, has formal university training in Chemistry and Physics (B.Sc.), Physical Chemistry (M.Sc.), and Pharmaceutical Chemistry (Ph.D.). His past research projects have focused on the mechanism of food-induced hemolytic crisis in G-6-PD deficiency (Favism), and the role of transition metals in biologically injurious processes involving free radicals. Prof. Chevion has also investigated the burn related injurious processes induced to the skin and eye tissues by toxic chemicals including warfare agents. Recently he focused on novel mechanisms of protection of the ischemic heart, brain, retina and intestine. These studies have been extended to the diabetic heart.
Through his research, Prof. Chevion has developed new drugs—currently being developed for clinical application—and novel modalities to counteract tissue injury mediated by free radicals. These drugs proved highly effective against inflammatory and other diseases.
Over the years, Prof. Chevion has edited and published two books, over one hundred and sixty fully refereed scientific papers, more than 400 abstracts and short papers, and invented 10 patents concerning antioxidant drugs.
In addition to his intensive academic activities, Prof. Chevion has been involved in establishing pioneering relationships and promoting cooperative activities with foreign (mainly Asian) governments, universities and research institutions. For his successful activities, Prof. Chevion was nominated for the King Boudoin International Development Prize in 1994. Prof. Chevion served as a consultant for the major corporations in Israel and other countries.
Dror Chevion (CEO).
Mr. Chevion is a successful Serial Entrepreneur with over 25 years of global experience in several industries. Earlier in his career, Mr. Chevion completed his BA in economics and business at the Hebrew University, Jerusalem and then began working for the Israeli Ministry of Finance, Department of the Budget. Mr. Chevion then continued to the private sector where he has held executive positions including VP Finance, VP Business Development, CEO, Managing Director, and Board Member. In addition, Mr. Chevion has served as Board Member in 2 publicly traded companies on the Tel-Aviv Stock Exchange. Mr. Chevion has an MBA from a joint program by J. L. Kellogg School of Management (Chicago, USA) and the Tel-Aviv University (Israel).
Peleg is an entrepreneurial executive with global experience in building, scaling up, and funding biotech and Agrifood businesses across various industries. He has an LL.B. Degree from Tel Aviv University, an MBA from INSEAD and is a Corporate Finance/IP attorney.
Peleg is currently President & Chief Commercial Officer at Blendhub - a multinational company that provides unique services for developing and producing powder-based food and nutrition.
Previously Peleg held positions including:
Affiliate Partner at Lindsay Goldberg - a NY based Private Equity firm ($14bn AUM);
Global Head of new technologies and Crop Enhancement at Syngenta, a Swiss Agriculture giant ($42bn acquired by ChemChina).
Director of Business Development at Crucell, a Dutch biotech focused on infectious diseases, vaccines, therapeutic proteins, and biosimilars (acquired by Johnson & Johnson).
Peleg started his career as an officer in the Israeli Air Force, leading R&D projects for aircraft and missiles. He is also a software engineer from the IDF computer academy (aka MAMRAM).